Fundraising FoxHillhouse Capital — 2018 Investments
4 investments dated 2018 · listed companies and verified rows first · show all
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life Sciences+3 more
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investorsARCH Venture Partners6 Dimensions CapitalBoyu CapitalGICSequoia CapitalWuXi Healthcare Ventures
A logistics company providing end-to-end supply chain services for food and consumer goods, from production to last-mile delivery, with focus on cold chain networks and supply chain digitalization through data analytics and automation.
B2B MarketplacesConstruction TechData & InfrastructureE-commerceEnterprise SoftwareFoodTechLogistics & Supply ChainSaaS
Co-investorsHongShan Capital GroupHundreds CapitalSoftBank Vision FundChina Structural Reform FundTencent Holdings
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.